Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18, 2023
By Michael Ganio, PharmD, MS, BCPS, FASHP
Brian Slomovitz, MD
  • Lucio Gordan, MD

Commentary
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

CancerNetwork® spoke with experts across multiple disciplines about the far-reaching impacts of the ongoing shortages of chemotherapy drugs including carboplatin and cisplatin, and how practices may be able to mitigate these challenges in the short and long term.

Michael Ganio, PharmD, MS, BCPS, FASHP, described the causes of carboplatin and cisplatin being in short supply across the United States and how the FDA is working with Chinese manufacturers to import these chemotherapy agents. Ganio, senior director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, stated that communication is paramount among all members of a care team to help prevent critical errors while treating patients with limited supplies of these drugs. He also spoke about how reaching out to local representatives may help address the issues resulting from these shortages.

“Advocacy is needed,” Ganio said. “Our policymakers need to know that these shortages are having a real-world impact, and that they need to be addressed.”

Brian Slomovitz, MD, MS, FACOG, spoke about how he is managing the ongoing shortages in the context of his gynecologic cancer care, including swapping one platinum-based drug for another during treatment. Slomovitz, a gynecologic oncologist, director of Gynecologic Oncology, and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida and a professor of Obstetrics and Gynecology at Florida International University, also described the challenges many practices across the country have due to lacking platinum-based drugs altogether.

“I know there are institutions that don't have [platinum-based chemotherapy],” Slomovitz said. “There are institutions that aren't able to give their patients the best standard-of-care therapy and aren't able to enroll patients in trials because of lack of therapy.”

Lucio N. Gordan, MD, addressed the financial impacts of these shortages, discussing how his practice has managed the rising prices of carboplatin and cisplatin in the country. Gordan, president and managing physician at Florida Cancer Specialists & Research Institute who sees patients in the state-wide practice's Gainesville Cancer Center, stated that efforts from major oncology organizations may help increase adequate access to chemotherapy drugs.

“It's very important that the large practices and institutions in the country stay united,” Gordan said. “The Community Oncology Alliance [COA], American Society of Clinical Oncology [ASCO], and others are trying to push legislation that would protect the consumer, the patients, and us to make sure that we have a proven supply.”

Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Reference

Temporary importation of CISplatin injection with non-U.S. labeling to address drug shortage. FDA. May 24, 2023. Accessed September 13, 2023. https://shorturl.at/eiPQZ

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
Advertisement

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.

FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome

Russ Conroy
August 6th 2025
Article

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.


EU approval of the agent is based on phase 2b ReNeu trial results, which met its primary end point of confirmed objective response rate in NF1-PN.

Mirdametinib Earns Conditional European Approval in Adult/Pediatric NF1-PN

Roman Fabbricatore
July 21st 2025
Article

EU approval of the agent is based on results from the phase 2b ReNeu trial, which met its primary end point of confirmed objective response rate in NF1-PN.

Related Content
Advertisement

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.

FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome

Russ Conroy
August 6th 2025
Article

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.


EU approval of the agent is based on phase 2b ReNeu trial results, which met its primary end point of confirmed objective response rate in NF1-PN.

Mirdametinib Earns Conditional European Approval in Adult/Pediatric NF1-PN

Roman Fabbricatore
July 21st 2025
Article

EU approval of the agent is based on results from the phase 2b ReNeu trial, which met its primary end point of confirmed objective response rate in NF1-PN.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.